

Array BioPharma records net loss

BOULDER - Biopharmaceutical company Array BioPharma (Nasdaq: ARRY) reported a net loss of \$33.7 million for the first quarter of fiscal year 2009, compared with a net loss of \$19.1 million for the same quarter a year ago.

The company's revenue is down from last year as well: \$5.7 million in revenue for the first quarter of fiscal year 2009 compared with \$6.6 million last year.

"By the end of calendar 2009, we anticipate obtaining proof-of-concept data on four additional clinical trials," Robert Conway, Array's chief executive officer, said in a statement. "Positive results on any of these trials will add significant value to Array and potential partners."